Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG plus cetuximab versus cetuximab alone in recurrent or progressive KRAS wild-type colorectal cancer
2010-023562-51Phase 3Terminated
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Imprime PGG + cetuximab with Cetuximab alone (2 arms). Primary endpoint: Progression-free survival. Started May 2011; status: terminated.
02
Drugs
odetiglucancetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-023562-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023562-51.